Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
Chen Hu(University of Science and Technology of China), Qingsong Liu(University of Science and Technology of China)
Cited by 22
Related Papers
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
|Oncotarget|2016|47
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
|Oncotarget|2015|46
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway
|Acta Pharmacologica Sinica|2020|33
Hydroxychloroquine facilitates autophagosome formation but not degradation to suppress the proliferation of cervical cancer SiHa cells
|Oncology Letters|2014|30
Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
|Acta Pharmaceutica Sinica B|2023|25